Tag Archives: Tendering and procurement

Yunnan Lists Coronary Stent Procurement Winners for Second Round

Leave a reply

Kunming, Sept 4, 2026 — Yunnan’s Government Procurement and Concession Center announced the online listing of selected products for the second round of national coronary stent volume-based procurement, launching a new procurement cycle running from Sept 15, 2026, to June 30, 2029, while terminating transaction eligibility for products under the previous agreement.

Policy Snapshot

AttributeDetail
IssuersYunnan Government Procurement and Concession Center; Yunnan Provincial Medical Security Bureau
DocumentNotice on the Work of Hanging Selected Products in the Second Round of National Coronary Stent Centralized Procurement
PlatformYunnan Medical Insurance Information Platform — Drug and Medical Consumables Procurement Management Subsystem
Procurement cycleSept 15, 2026 – June 30, 2029
Agreement structureTripartite (one-year renewable contracts)
Key actionsOnline listing of selected products; price governance for non-selected products

Key Provisions

  • Selected product listing — Winning products are listed on the procurement subsystem for transaction and settlement. Products listed under the previous agreement period are simultaneously delisted.
  • Distributor designation — Selected enterprises independently designate distribution partners through the procurement subsystem and establish delivery relationships. Annual tripartite agreements are signed to define rights and obligations.
  • Price governance — Non-selected products with excessively high listed prices are assigned “red/yellow” warning labels. Enterprises receiving targeted notifications must adjust prices accordingly; those without notifications are outside this round’s price governance scope.
  • Dynamic listing compliance — Non-selected products must follow the dynamic listing rules under Yunnan Medical Security Bureau [2022] No. 92 for application and price adjustment.
  • System registration — Enterprises without existing accounts must complete registration on the procurement subsystem per the March 20, 2024, platform notice.

Market Impact Analysis

The nearly three-year procurement cycle provides supply certainty for coronary stent manufacturers and cardiology departments across Yunnan’s public hospital network. By automatically terminating the previous agreement and activating the new second-round listings, regulators are ensuring a clean transition without overlapping transaction eligibility that could confuse hospital procurement officers.

The “red/yellow” warning system for non-selected products is a particularly consequential market-shaping tool. By flagging overpriced non-winners, the mechanism extends the price compression effect of national volume-based procurement beyond the selected supplier pool, pressuring the entire competitive set to align with national benchmarks or risk exclusion from hospital formularies. This creates a de facto price ceiling for the coronary stent market in Yunnan, compressing margins for both domestic and international manufacturers that failed to secure selected status.

For selected enterprises, the ability to independently designate distributors offers operational flexibility, though the annual tripartite agreement structure introduces yearly renegotiation leverage points for hospitals. The requirement for enterprises without platform accounts to register before participating ensures full traceability in the procurement chain but may delay market entry for smaller manufacturers unfamiliar with Yunnan’s digital procurement infrastructure.

Forward-Looking Statement

Industry analysts expect the Sept 15 launch to serve as a template for other provincial procurement centers rolling out the national coronary stent second-round agreement in the coming weeks. The three-year cycle ending in mid-2029 gives manufacturers long-term volume visibility, though the annual distributor agreement renewals create recurring compliance checkpoints. The red/yellow price warning system is likely to be replicated across other high-value device categories—such as orthopedic implants and pacemakers—as provincial regulators seek to manage non-selected product pricing without resorting to formal delisting. Companies with coronary stent portfolios should monitor Yunnan’s platform closely, as the dynamic listing rules for non-selected products may trigger additional price adjustment mandates before year-end.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27794&CatalogId=3

China Approves 13th Batch of National Drug Procurement Information Changes

Leave a reply

Beijing, Sept 4, 2026 — China’s National Drug Centralized Procurement Office approved the 13th batch of information changes for selected drugs under the national volume-based procurement program, allowing winning manufacturers to update marketing authorization holders, production sites, specifications, packaging, and corporate names without losing their selected status.

Policy Snapshot

AttributeDetail
IssuerNational Drug Centralized Procurement Joint Office
DocumentNotice on Information Changes of Selected Drugs in National Centralized Procurement (13th Batch)
Effective dateSept 4, 2026
ScopeSelected drugs under national volume-based procurement
Permitted changesMarketing authorization holder; manufacturer; specifications; packaging; corporate name
ConditionSelected enterprises must meet specified eligibility criteria
Action requiredInformation linkage updates; platform listing adjustments; procurement coordination

Key Provisions

Under the National Drug Centralized Procurement Document and related regulations, winning enterprises that satisfy defined conditions may modify critical product and corporate information while retaining their selected procurement qualification. The office verified enterprise application materials before granting approval for the 13th batch of changes. All relevant parties—including medical institutions, distributors, and procurement platforms—must promptly complete information synchronization, online listing updates, and purchasing workflow adjustments to reflect the revised drug details.

Market Impact Analysis

The 13th batch approval signals continued regulatory flexibility within China’s rigid national procurement framework, acknowledging that corporate restructuring, manufacturing consolidation, and product line optimization are inevitable in a market undergoing rapid consolidation. By allowing marketing authorization holder and production site transfers without stripping selected status, regulators are preventing supply disruptions that could arise if every corporate change triggered automatic re-tendering.

For pharmaceutical companies, the change mechanism provides a critical pathway to optimize manufacturing footprints and transfer assets between subsidiaries without sacrificing the hard-won volume commitments secured through national bidding. However, the requirement to meet unspecified “certain conditions” implies that not all change requests are automatically approved, creating a compliance gate that favors well-resourced enterprises capable of navigating administrative verification.

For hospitals and procurement platforms, the batch release demands immediate system updates to ensure that purchasing records, invoice matching, and inventory management align with the revised drug information. Failure to synchronize could result in settlement delays or compliance flags during audits.

Forward-Looking Statement

Industry analysts expect the national procurement office to maintain a regular cadence of information change approvals—likely quarterly or monthly—as the volume-based procurement program matures and corporate restructuring accelerates across the domestic pharmaceutical sector. The 13th batch suggests the approval pipeline is processing applications efficiently, with minimal backlog. Companies planning mergers, acquisitions, or manufacturing transfers for selected products should file change applications proactively, as the office’s willingness to approve such modifications reduces the regulatory risk traditionally associated with post-award corporate actions. The batch release also sets a template for provincial procurement alliances, many of which are expected to adopt similar change-management protocols to ensure supply continuity across decentralized procurement networks.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/gjsdcg/2026/09/04/24314.shtml

Shanghai TCM Procurement Disqualification Targets Herb Suppliers

Leave a reply

Shanghai, Sept 3, 2026 — Shanghai’s Medical Procurement Center said it will revoke procurement qualifications for certain selected traditional Chinese medicine (TCM) herb slices starting Sept 5, 2026, following a national alliance decision to disqualify individual enterprises for violations and place them on a non-compliance list.

Policy Snapshot

AttributeDetail
IssuerShanghai Medical Centralized Bidding and Procurement Affairs Management Center
DocumentNotice on the Revocation of Qualification for Procuring Certain Selected Traditional Chinese Medicine Herbs
Effective dateSept 5, 2026
Legal basisNational TCM Decoction Pieces Alliance Procurement Office announcement on canceling selected enterprise qualifications and listing violators
ScopeSelected TCM herb slices (decoction pieces) under the national alliance procurement program
Affected partiesMedical institutions with contracted purchase volumes for the disqualified varieties

Key Provisions

  • Qualification revocation — Starting Sept 5, the selected procurement status of the relevant TCM herb slices is canceled. Medical institutions must update their systems and complete invoice verification accordingly.
  • Volume fulfillment mechanism — Hospitals with contracted purchase volumes for the disqualified varieties may procure alternative selected products to fulfill their contracted obligations, with such purchases counted toward completion of the original volume commitments.
  • Compliance enforcement — The action aligns with the national TCM decoction pieces alliance’s penalty decision against enterprises found in violation of procurement rules.

Market Impact Analysis

The disqualification immediately removes one or more suppliers from Shanghai’s TCM herb procurement channel, forcing medical institutions to redirect orders to remaining qualified manufacturers within the national alliance catalog. For hospitals with active contracts for the affected varieties, the alternative procurement provision prevents supply disruptions while ensuring volume targets are met, though switching suppliers may involve re-qualification of product specifications and potential price adjustments.

For the broader TCM decoction pieces market, the enforcement action signals that the national alliance procurement regime—which has historically faced challenges with quality consistency and supply reliability—is actively penalizing non-compliant participants. This may strengthen the bargaining position of compliant suppliers and accelerate consolidation among smaller herb processors unable to meet alliance standards.

Forward-Looking Statement

Industry analysts expect the national TCM decoction pieces alliance to publish additional disqualification notices across other member provinces in the coming weeks, as the coordinated procurement framework applies penalties uniformly. Medical institutions in Shanghai should complete system updates and supplier transitions by the Sept 5 deadline to avoid procurement compliance gaps. The volume fulfillment flexibility—allowing alternative selected products to count toward original commitments—suggests regulators are prioritizing supply continuity over rigid contractual adherence, a pragmatic approach that may be replicated in future enforcement actions. Companies remaining on the qualified supplier list are positioned to capture redirected volume, potentially boosting market share in the fragmented TCM herb slices segment.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/09/03/24299.shtml